TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed written informed consent.~2. Original diagnosis and/or histological confirmation of high-grade serous, high-grade endometrioid, undifferentiated/unclassifiable epithelial ovarian, fallopian tube or primary peritoneal cancer.~3. Time from the last line of platinum-based chemotherapy of less than 6 months.~4. Received at least 3 prior chemotherapy-containing regimens.~5. Age ≥18 years.~6. Ability to comply with protocol requirements.~7. Patients are not of childbearing potential or they must agree to use a physical method of contraception.~Exclusion Criteria:~1. Disease that progressed while receiving initial line of platinum-based chemotherapy.~2. Received fewer than 3 prior chemotherapy-containing regimens.~3. Prior therapy with single-agent gemcitabine.~4. Prior history of hypersensitivity to gemcitabine.~5. Prior chemotherapy, radiation (other than short cycle of radiation to reduce bone pain), treatment with a VEGF inhibitor, PARP inhibitor or immunotherapy within 21 days of first receipt of study drug. Hormone therapy within 14 days of first receipt of study drug.~6. Residual side effects from chemotherapy or radiation, which have not gotten better except for nerve pain or tingling or hair loss.~7. Patients who have a history of another type of cancer diagnosed within the past 5 years, with the exception of adequately treated non-melanoma skin cancer curatively treated cervical cancer or ductal carcinoma in situ (DCIS) of the breast.~8. Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics.~9. Presence of any serious illnesses, serious medical conditions, serious medical history, active bacterial or viral infections including hepatitis B or C, or known to be HIV positive.~10. Currently pregnant, lactating or breastfeeding.~11. History of blocked intestines because of ovarian cancer, unless fully resolved.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
- Arm B (Type: EXPERIMENTAL): NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>=18 years of age and treated with simvastatin 10 mg or 20 mg for at least 6 weeks and LDL-C levels of \> 2.5 mmol/L to \<=4.20 mmol/L (97 mg/dL to 160 mg/dL) at Visit 1.~* history of coronary heart disease (type II diabetic patients \> 30 years old with no CHD)~* triglycerides \<= 4.00 mmol/L drawn, and liver transaminases (ALT, AST) \<=50% above the upper limit of normal at Visit 2, with no active liver disease, and/or creatine kinase (CK) \<=50% above the upper limit of normal~Exclusion Criteria:~* subjects with Body Mass Index \>=35 kg/sqm at Visit 1~* alcohol consumption \> 14 drinks per week~* pregnant or lactating~* treated with any other investigational drug within 30 days prior Visit 1~* previously treated with ezetimibe or participated in a clinical study with ezetimibe~* any condition or situation which, in the opinion of the investigator, might pose a risk to the patient or interfere with participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ezetimibe (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quell Opioid Reduction and Pain Relief in Patients With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female greater than or equal to 18 year of age at visit one.~2. Documented diagnosis of metastatic breast, prostate or colorectal cancer with a prognosis of 6 month or greater as determined by the primary oncologist.~3. Visual evidence that subject owns a smart phone and is able to use basic mobile applications such as downloading an app, opening the app, and performing one simple task within the app.~4. Subject speaks and reads English fluently.~5. Subject able to understand and grant informed consent.~6. Live in an area with cellular data connectivity available as provided by the subject.~7. Documented adherence with clinic follow up visits per medical records.~8. Subject using at least one opioid medication on a daily basis.~Exclusion Criteria:~1. Subject has a cardiac pacemaker, implanted defibrillator or other implanted electronic device.~2. Inability to complete subjective data as required; e.g. on mobile application and questionnaires.~3. Does not live in an area with suitable cellular data connectivity.~4. Has infrequent scheduled clinic visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quell Device (Type: ACTIVE_COMPARATOR): Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
- Sham Quell Device (Type: SHAM_COMPARATOR): Identical to Active Comparator, but provides sub-therapeutic electronic stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Systolic dysfunction (LVEF ≤ 35% by echo assessment within 6 months before enrolment)~* No requirement for hospital admission for diagnostic work up or elective treatment to define etiology and/or treatment plan~* Already on optimal standard HF treatment based on individual tolerance, including cardiac resynchronization therapy (CRT)/ICD device according to current guidelines~* At least 2 hospital admissions for HF in the 6 months before enrolment, the most recent one within 30-90 days before enrolment with requirement for inotrope administration~Exclusion Criteria:~* Participant in other studies in the last 30 days~* Life expectancy \< 1 year for comorbid conditions other than HF~* Pregnancy, lactation, childbearing potential unless on adequate contraception~* Acute coronary syndromes, percutaneous or surgical revascularization, valve surgery performed within 8 weeks before enrolment~* Planned percutaneous or surgical procedures (except for heart transplantation)~* CRT within 6 months before enrolment~* Cardiogenic shock~* Supine systolic BP \< 85 mmHg~* Severe liver insufficiency (\>three-fold increase in AST-ALT )~* Sever chronic kidney dysfunction (estimated GFR \< 30 ml/min)~* Sustained ventricular tachycardia~* Severe chronic or current acute infection (temperature \>38 C, WBC \>15,000/mm3)~* Severe chronic obstructive pulmonary disease (FEV1 \<30% predicted or on oxygen therapy)~* Severe persistent anemia (Hb \< 10 g/l))~* ACHF exacerbation due to conditions requiring specific treatment (e.g. anemia, atrial fibrillation, supraventricular tachycardia ) Documented low compliance or unavailable for programmed follow-up visits and phone contact

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Diuretics (Type: ACTIVE_COMPARATOR): Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
- Levosimendan (Type: EXPERIMENTAL): Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Infrasound Exposure on Measures of Endolymphatic Hydrops

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age of 18 to 60 years~2. Absence of otologic symptoms based on screening questionnaire~3. Normal otoscopic examination~4. Audiometric thresholds less than 25 dB at 250, 500, 750, 1000 Hz.~Exclusion Criteria:~1. Age less than 18 or greater than 60 years. Age greater than 60 is considered an exclusion criterion as prior studies have demonstrated elevated VEMP thresholds attributed to age~2. Presence of any positive symptom on the questionnaire~3. Thresholds greater than 25 dB at the tested frequencies~4. Abnormal otoscopic examination (e.g., ear canal occlusion, tympanic membrane perforation, tympanic membrane retraction)~5. History of prior ear surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Block 1 (Type: None): Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
- Block 2 (Type: None): Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
- Block 3 (Type: None): Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
- Block 4 (Type: None): Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
- Block 5 (Type: None): Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
- Block 6 (Type: None): Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~i. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.~ii. Understands and agrees to comply with planned study procedures. iii. Male or female adult ≥18 - 95 years of age at time of enrolment. iv. Laboratory-confirmed SARS-CoV-2 infection in any specimen \< 5 days prior to randomization.~v. At least one of the following:~1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) or~2. Clinical assessment (evidence of rales/crackles on exam) AND SpO2 ≤94% on room air vi. Women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study.~Exclusion Criteria:~i. History of liver failure ii. History of stage 4 severe chronic kidney disease or requiring dialysis iii. Self-reported pregnant or breast feeding. iv. Allergy to hydroxychloroquine or choloroquine v. Known contraindication to hydroxychloroquine, including retinopathy, G6PD deficiency, QT prolongation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine 400 mg 2x day by mouth on day 1, followed by 200 mg 2x day by mouth days 2-5
- Usual Care (Type: NO_INTERVENTION): usual care for hospitalized patients diagnosed with COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~These were chosen based on a review of the major studies evaluating risk factors for post-ERCP pancreatitis. Any of the following factors placing a patient at high risk (\>10%) of post ERCP pancreatitis:~* Patient characteristics: Prior history of post-ERCP pancreatitis, prior history of acute pancreatitis, suspected Sphincter of Oddi dysfunction, or normal bilirubin;~* Procedure related factors: Moderate (6-15 attempts) and difficult (\>15 attempts) bile duct cannulation, balloon dilation of the biliary sphincter, pre-cut papillotomy, pancreatic sphincterotomy.~Exclusion Criteria:~* Ongoing acute or chronic pancreatitis;~* Previous biliary sphincterotomy;~* Contra-indications to non-steroidal anti-inflammatory medications (allergy, reduced renal function, recent upper gastrointestinal bleeding);~* Ingestion of an NSAID ( nonsteroidal anti-inflammatory drug) in the previous 7 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo suppository (Type: PLACEBO_COMPARATOR): None
- diclofenac suppository (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Digestive NET histopathologically proven, poorly-differentiated~* Inoperable/advanced NET (Tumor relapse inoperable or metastatic with no surgical indication).~* Tumor samples should be made available for analysis(diagnostic biopsy, surgical specimen)~* measurable disease defined by at least one lesion wich can be measured by at least one dimension :~  * equal or superior to 20 mm ( by conventional methods )~ * equal or superior to 10 mm (by spiral scan within 28 days before the beginning of the treatment)~* Performance status WHO ≤ 2.~* Adequate organ function :~  * hematology (absolute neutrophil count equal or superior to 1,5 x 10\*9/l , platelet equal or superior to 100 x 10\*9/l),~ * clearance of creatinine equal or superior to 60 ml/min),~ * AST/ALT ≤ 5 N, PAL ≤ 5 N, total bilirubin ≤ 2N.~* the selected women must be post-menopausal woman or surgically castrated or have to accept an effective contraception for the duration of the treatment and 3 month after.Women who are old enough to procreate must have a negative pregnancy test within the 72 hours of the beginning of the treatment.They must not be pregnant or to breastfeed.the selected men and theirs partners must be sterile or use an effective contraception for the duration of the treatment and 3 month after.~Exclusion Criteria:~* Hypersensitivity to sunitinib.~* Contraindication to sunitinib, including uncontrolled hypertension, medical history of cerebrovascular accident, unstable cardiac pathology despite optimal medical therapy (myocardial infarction within the 6 months prior to study drug administration, severe/unstable angina ), active hemorrhagic syndrome or concomitant treatment with anticoagulants.~* Any severe acute or chronic co-morbid that may compromise to comply with study participation: uncontrolled infection, symptomatic congestive heart failure, liver disturbance, chronic renal failure, active gastro-duodenal ulcer (nonexhaustive list).~* Known brain metastases.~* Diagnosis of any second malignancy within the last 3 years, except for basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri~* Current treatment on another clinical trial.~* Prior treatment with an investigational agent within 4 weeks.~* Prior treatment with intravenous biphosphonates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient treated (Type: EXPERIMENTAL): patient who receive sunitinib (SUTENT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Program of Physician Supervision to Improve the Quality of Patient Referrals From Nurse Practitioners and Physician Assistants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
All nurse practitioners and physician assistants in the Mayo Clinic Health System

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NPs & PAs referral discussions with a supervising physician (Type: EXPERIMENTAL): required consultations between NPs and PAs and their supervising physicians
- NPs and PAs - no consultations with supervising physisians (Type: OTHER): NPs and PAs who are not required to discuss patient referrals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* hs CRP \>3mg/L and \<10 mg/L~Exclusion Criteria:~* Active infection~* Systemic Inflammatory Disease~* Currently on warfarin~* Cr \> 2.0~* Fish Allergy~* Pregnancy or unwillingness to use some form of birth control

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Active Arm:~1000 mg Lemon flavored Capsules. Three capsules every morning.
- 2 (Type: PLACEBO_COMPARATOR): Placebo Arm:~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antihistamines in Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 18, male and female.~* Patients who carry the diagnosis of Eosinophilic Esophagitis (EoE) based on esophageal biopsies obtained within 6 months prior to enrollment (\>15 eosinophils per hpf on at least 2 esophageal levels)~* Subjects must be able to give appropriate informed consent~Exclusion Criteria:~* Not willing or able to sign consent.~* Patients who have used topical or systemic corticosteroid therapy for any reason in the previous 6 weeks.~* Patients who have been treated with acid-suppressing medications (PPI or H2 receptor antagonists) in the previous 6 weeks.~* Patients on immunosuppressive or immunomodulating medications in the previous 6 weeks.~* Patients with known allergies or hypersensitivity to anti-histamines.~* Patients who have contraindications to the procurement of esophageal biopsies including patients who have known bleeding disorders, a history of bleeding diathesis, or who are currently using warfarin or clopidogrel.~* Patients who have a contraindication to the performance of an esophagogastroduodenoscopy (EGD) including previous cardiopulmonary arrest during an endoscopic procedure.~* Patients who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Participants receive Famotidine 40 mg tab twice daily by mouth and Loratadine 10 mg tab once daily by mouth for 12 weeks.
- Placebo Group (Type: PLACEBO_COMPARATOR): Participants receive Famotidine placebo tablet matching Famotidine orally twice daily for 12 weeks, and Loratadine placebo tablet matching Loratadine orally daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues